Since increased ROS and ATP shortage in skeletal muscle are known to be involved in sarcopenia, especially uremic sarcopenia cases (13–15), we speculated that XOR inhibitor treatment has effects to protect against sarcopenia through preservation of skeletal muscle mass and function by decreased ROS production and ATP enhancement in HD patient skeletal muscle tissues. Here, XDH is linked to sarcopenia.